Want to see HK:6086 full AI Analyst Report?
Top Page
Fangzhou Inc.
(6086)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$0.75
▼(-79.45% Downside)
Action:Reiterated
Date:06/19/26
The score is supported mainly by improving financial performance in 2025 (revenue growth, profitability turnaround, and positive free cash flow). It is held back by weak technicals (price below key moving averages with negative MACD and low RSI) and a stretched valuation (high P/E with no dividend yield provided).
Positive Factors
2025 Operational Turnaround
Revenue growth of about 19% alongside a return to positive operating profit and net income indicates the business regained operating traction in 2025. If maintained, this combination can support scale benefits, reinvestment, and a more durable earnings base after prior losses.
Negative Factors
Thin Margins
Despite the 2025 turnaround, net margin was only about 0.3% and operating margin remained low, while gross margin declined versus 2022–2024. Thin and weakening margins leave little buffer against cost pressure and make earnings durability dependent on further operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Operational Turnaround
Revenue growth of about 19% alongside a return to positive operating profit and net income indicates the business regained operating traction in 2025. If maintained, this combination can support scale benefits, reinvestment, and a more durable earnings base after prior losses.
Read all positive factors
Fangzhou Inc. (6086) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.02B
Dividend YieldN/A
Average Volume (3M)284.65K
Price to Earnings (P/E)104.6
Beta (1Y)1.72
Revenue Growth38.59%
EPS GrowthN/A
CountryHK
Employees494
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,385,448,500
10 Day Avg. Volume452,950
30 Day Avg. Volume284,650
Financial Highlights & Ratios
PEG Ratio-2.25
Price to Book (P/B)17.52
Price to Sales (P/S)0.76
P/FCF Ratio41.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.00Price Target Upside65.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$4.47B
Fangzhou Inc. Business Overview & Revenue Model
Company Description
Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health is...
Fangzhou Inc. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
62
Positive
Cash Flow
68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.53B | 2.71B | 2.43B | 2.20B | 1.76B |
| Gross Profit | 559.44M | 515.94M | 487.41M | 441.20M | 262.74M |
| EBITDA | 16.05M | -739.87M | -174.76M | -123.00M | -220.66M |
| Net Income | 11.83M | -854.88M | -196.79M | -383.30M | -303.96M |
Balance Sheet | |||||
| Total Assets | 814.24M | 664.09M | 521.37M | 582.57M | 426.54M |
| Cash, Cash Equivalents and Short-Term Investments | 377.52M | 261.51M | 146.32M | 134.91M | 84.66M |
| Total Debt | 35.81M | 50.89M | 49.72M | 1.99B | 18.27M |
| Total Liabilities | 660.44M | 532.39M | 2.42B | 2.50B | 2.07B |
| Stockholders Equity | 153.79M | 131.70M | -1.90B | -1.92B | -1.34B |
Cash Flow | |||||
| Free Cash Flow | 65.40M | 15.63M | 16.63M | -65.42M | -262.72M |
| Operating Cash Flow | 70.86M | 19.54M | 22.28M | -59.28M | -246.43M |
| Investing Cash Flow | 1.52M | -111.51M | 16.42M | 14.31M | -4.32M |
| Financing Cash Flow | -16.96M | 119.62M | -29.31M | 82.23M | -11.41M |
Fangzhou Inc. Technical Analysis
Negative
3.63
Price Trends
0.73
Positive
0.87
Negative
1.61
Negative
Market Momentum
<0.01
Negative
51.88
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6086, the sentiment is Negative. The current price of 3.63 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.73, and above the 200-day MA of 1.61, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6086.
Fangzhou Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$976.17M | -13.80 | -3.87% | ― | 8.73% | 80.38% | |
53 Neutral | HK$1.02B | 104.59 | 3.67% | ― | 38.59% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.64B | -12.51 | -16.60% | ― | ― | ― | |
43 Neutral | HK$579.60M | -11.40 | -8.62% | 2.98% | 2.06% | -298.25% | |
42 Neutral | HK$1.12B | 34.22 | -3.95% | ― | -8.00% | 51.26% | |
42 Neutral | HK$970.43M | -8.81 | -39.21% | ― | ― | ― |
* Healthcare Sector Average
HK:6086
Fangzhou Inc.
0.74
-4.15
-84.94%
HK:9886
Dingdang Health Technology Group Ltd.
0.80
-0.08
-9.66%
HK:1228
CANbridge Pharmaceuticals Inc.
1.90
-0.75
-28.30%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
0.81
0.09
11.81%
HK:2898
Sunho Biologics,Inc.
6.39
-1.27
-16.58%
HK:2563
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
4.30
-4.37
-50.40%
Fangzhou Inc. Corporate Events
Fangzhou boosts AI investment as interim revenue and user base surge
Aug 27, 2026
Fangzhou reported strong interim results for the first half of 2026, underpinned by accelerated investment in its proprietary XingShi large language model to enhance AI-driven solutions across clinical data management, decision support, and operat...
Fangzhou Inc. Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 17, 2026
Fangzhou Inc., a Cayman Islands-incorporated company listed in Hong Kong under stock code 6086, is overseen by a board that includes executive, non-executive and independent non-executive directors, reflecting a governance framework aligned with H...
Fangzhou Inc. Shareholders Approve All AGM Resolutions and Capital Mandates
Jun 16, 2026
Fangzhou Inc. reported that shareholders at its annual general meeting on June 16, 2026, approved all resolutions by poll, including the adoption of the audited consolidated financial statements for the year ended December 31, 2025. The meeting re...
Fangzhou Inc. Sets Out Board Composition and Committee Roles
Jun 16, 2026
Fangzhou Inc. has announced the current composition of its board of directors, naming David McKee Hand as chairman and non-executive director alongside three executive directors and three independent non-executive directors. The company has also d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.